Horizon Therapeutics initiated with an Overweight at Wells Fargo Wells Fargo analyst Derek Archila initiated coverage of Horizon Therapeutics with an Overweight rating and $137 price target. The analyst believes there is upside potential to out year Krystexxa and Uplizna estimates. Even factoring in future competition, "we view these franchises as relatively durable," Archila tells investors in a research note.Our Take: "Very solid and longer-term growth play in the biotech and drug sectors." $HZNP, Horizon Therapeutics Public Limited Company / H1 Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal. If you liked this article, please click the LIKE (thumbs up) button. Feel free to leave any comments, question, or opinions. (Sign-up if you haven't already done so). Follow us/bookmark us and check back occasionally for additional articles or comments on our page... Wild Tiger Trading - start/main page. .